| Log in

Pharma M&A is an absolute seller’s market: Alpesh Dalal of Lupin

17 November, 2015

Lupin Ltd, India’s second largest drugmaker by market value, had been pursuing inorganic expansion during 2007-11, but had gone quiet on the mergers and acquisitions (M&A ....

To read the Full Story

Definitive news, exclusives, analyses and videos

  • Exclusive reporting, expert analysis and commentary on PE/VC/M&A deals & dealmakers
  • Daily, weekly and monthly curated newsletters on the deal ecosystem in India
  • Breaking news alerts
  • Participation in marquee events at concessional rates

Comprehensive | Accurate | Unbiased | Impeccably sourced


Leave Your Comment
Lupin to buy American generic drugmaker GAVIS for $880M in biggest overseas pharma M&A

Lupin to buy American generic drugmaker GAVIS for $880M in biggest overseas pharma M&A

Anuradha Verma 3 years ago
Lupin Ltd, India’s third-largest drugmaker by sales, has agreed to acquire...
Lupin to buy remaining 40% stake in South African generic drugmaker Pharma Dynamics

Lupin to buy remaining 40% stake in South African generic drugmaker Pharma Dynamics

Jasleen Kaur Batra 3 years ago
Mumbai-based pharma major Lupin Ltd has entered into an agreement to acquire the...
Lupin eyes acquisitions of up to $1B to expand overseas

Lupin eyes acquisitions of up to $1B to expand overseas

Jasleen Kaur Batra 4 years ago
Mumbai-based pharma major Lupin Ltd, seen as a conservative drugmaker compared...
No Comments

Pharma M&A is an absolute seller’s market: Alpesh Dalal of Lupin

Powered by WordPress.com VIP